Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Denosumab and zoledronic acid for patients with postmenopausal osteoporosis: a review of the clinical effectiveness, safety, cost effectiveness, and guidelines
. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2012 Authors' conclusions Denosumab and zoledronic acid were shown to be safe and effective in patients with postmenopausal osteoporosis who have switched from oral bisphosphonates, though whether these patients experienced decline or were intolerant of oral bisphosphonate therapy is unclear.
Compliance rates are generally inadequate in patients taking oral bisphosphonates and improved in patients on denosumab therapy. Clinical practice guidelines recommend that zoledronic acid, denosumab, strontium ranelate, or calcitonin be used to treat patients who are intolerant to oral bisphosphonate therapy. No evidence for the cost effectiveness of denosumab or zoledronic acid in patients experiencing decline on oral bisphosphonate treatment was identified.
Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal; Bone Density Conservation Agents; Cost-Benefit Analysis; Diphosphonates; Imidazoles; Osteoporosis, Postmenopausals Language Published English Country of organisation Canada English summary An English language summary is available. Address for correspondence Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, K1S 5S8 Ottawa, Ontario Canada Email: htainfo@cadth.ca AccessionNumber 32012000692 Date abstract record published 29/09/2012 |